Industry News
Biotechnology Industry News
More than a year after licensing…
More than a year after licensing its PD-1xVEGF bispecific, Merck & Co. has finally unveiled the first clinical data from the antibody. The results suggest the drug boasts similar safety and efficacy in non-small cell
Following its recently announced…
Following its recently announced partnership with Novo Nordisk, OpenAI is introducing a new reasoning model, GPT-Rosalind, to support research in biology, drug discovery and translational medicine.
Kailera Therapeutics appears to…
Kailera Therapeutics appears to have set a new benchmark for biotech IPOs with an upsized $625 million offering to fund its pipeline of obesity therapies.
Chinese companies now represent…
Chinese companies now represent 50% of global out-licensing deals, with U.S. companies dropping to about 28%, according to SynBioBeta data.
After helping guide Metsera…
After helping guide Metsera through its high-profile, $10 billion acquisition by Pfizer last year, Matthew Lang is swinging over to a different obesity biotech as chief operating officer and general counsel at Structure Therapeutics.
The traditional gold standard of…
The traditional gold standard of clinical trials with a randomized, placebo-controlled design involving hundreds of patients has inherently been unfeasible for the rare disease community.
With a few chemical tweaks and…
With a few chemical tweaks and some dutiful protein partners, a new biotech from Flagship Pioneering thinks it has cracked the code to turn DNA into a brand-new class of therapeutics.
China’s biotech rise has been a…
China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma executives. But to Roivant CEO Matt Gline, the country is nothing more than a red herring.
Learn how early intervention can…
Learn how early intervention can help drug developers convert suboptimal formulations into scalable, clinically viable solutions.
After its bet on a rare eye…
After its bet on a rare eye disease gene therapy ended in a phase 3 fail, Johnson & Johnson is returning the asset to sender as MeiraGTx buys back back full rights to botaretigene sparoparvovec
Storm Therapeutics has closed a…
Storm Therapeutics has closed a $56 million series C financing and launched a Phase 2 trial of its lead asset for sarcoma patients.
Aligos Therapeutics has secured a…
Aligos Therapeutics has secured a $25 million upfront fee from hepatology biopharma Amoytop in exchange for the China rights to its phase 2-stage chronic hepatitis B virus (HBV) treatment.
A slow start to 2026 has put…
A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing the already limited funding opportunities available for startups.
In a complex therapeutic…
In a complex therapeutic landscape, WuXi AppTec is simplifying the path from discovery to patient. Find out how.
The Spanish government has…
The Spanish government has announced a goal to raise a $200 million venture capital fund to launch the Spain-Boston biotechnology initiative to expand international collaboration.
The steady stream of IPOs…
The steady stream of IPOs evaporated almost as quickly as it had appeared. So what happened?
Terremoto Biosciences has spelt…
Terremoto Biosciences has spelt out how the California biotech will use a $108 million series C round to continue its efforts to broaden the covalent drug alphabet.
The FDA’s newly launched…
The FDA’s newly launched plausible mechanism framework may have been forged in the image of individualized therapies, but its principles are not confined to the bespoke, Teresa Buracchio, M.D., head of the FDA’s Office of
The former leaders of SpringWorks…
The former leaders of SpringWorks Therapeutics are back with a new biotech venture that is already buzzing from a $300 million series A.
After initiating a wind-down more…
After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a partner via a reverse merger with Obsidian Therapeutics that will take oncology-focused Obsidian public.